Advertisement

One-Year Ischemic and Bleeding Events According to Renal Function in Patients With Non–ST-Segment Elevation Acute Coronary Syndromes Treated With Percutaneous Coronary Intervention and Third-Generation Antiplatelet Drugs

      The optimal antiplatelet therapy of patients with non–ST-segment elevation acute coronary syndromes (NSTE-ACS) and chronic kidney disease (CKD) remains unknown. This study included 2,364 patients with NSTE-ACS undergoing predominantly percutaneous coronary intervention (PCI), who were randomized to ticagrelor or prasugrel in the ISAR-REACT 5 trial. Estimated glomerular filtration rate (eGFR) was calculated using the Chronic Kidney Disease Epidemiology Collaboration equation. The primary end point was 1-year mortality. Overall, there were 85 deaths (3.6%): 6 deaths (17.1%) in patients with eGFR <30, 31 deaths (6.9%) in patients with eGFR 30 to <60, 34 deaths (3.0%) in patients with eGFR 60 to <90, and 14 deaths (2.0%) in patients with eGFR ≥90 ml/min/1.73 m2; adjusted hazard ratio (HR)=1.15, 95% confidence interval (CI) 1.01 to 1.31; p = 0.033 for 10 ml/min/1.73 m2 decrement in the eGFR. Bleeding occurred in 129 patients (5.5%): 7 bleeds (20.2%) in patients with eGFR <30, 36 bleeds (8.0%) in patients with eGFR 30 to <60, 64 bleeds (5.6%) in patients with eGFR 60 to <90, and 22 bleeds (3.1%) in patients with eGFR ≥90 ml/min/1.73 m2; adjusted HR=1.11 (1.01 to 1.23); p = 0.045 for 10 ml/min/1.73 m2 decrement in the eGFR. One-year mortality and bleeding did not differ significantly between ticagrelor and prasugrel in all categories of impaired renal function. In conclusion, in patients with NSTE-ACS undergoing PCI with drug-eluting stents and third-generation antiplatelet drugs, impaired renal function was independently associated with higher risk of 1-year mortality and bleeding. The ischemic and bleeding risks appear to differ little between ticagrelor and prasugrel in all categories of impaired renal function.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to American Journal of Cardiology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Goldenberg I
        • Subirana I
        • Boyko V
        • Vila J
        • Elosua R
        • Permanyer-Miralda G
        • Ferreira-González I
        • Benderly M
        • Guetta V
        • Behar S
        • Marrugat J.
        Relation between renal function and outcomes in patients with non-ST-segment elevation acute coronary syndrome: real-world data from the European public health outcome Research and Indicators Collection Project.
        Arch Intern Med. 2010; 170: 888-895
        • Fox CS
        • Muntner P
        • Chen AY
        • Alexander KP
        • Roe MT
        • Cannon CP
        • Saucedo JF
        • Kontos MC
        • Wiviott SD
        • Acute Coronary Treatment and Intervention Outcomes Network Registry
        Use of evidence-based therapies in short-term outcomes of ST-segment elevation myocardial infarction and non-ST-segment elevation myocardial infarction in patients with chronic kidney disease: a report from the National cardiovascular Data Acute Coronary Treatment and Intervention Outcomes Network registry.
        Circulation. 2010; 121: 357-365
        • Rozenbaum Z
        • Benchetrit S
        • Minha S
        • Neuman Y
        • Shlezinger M
        • Goldenberg I
        • Mosseri M
        • Pereg D.
        The effect of admission renal function on the treatment and outcome of patients with acute coronary syndrome.
        Cardiorenal Med. 2017; 7: 169-178
        • Pilmore HL
        • Xiong F
        • Choi Y
        • Poppe K
        • Lee M
        • Legget M
        • Kerr A.
        Impact of chronic kidney disease on mortality and cardiovascular outcomes after acute coronary syndrome: A nationwide data linkage study (ANZACS-QI 44).
        Nephrology (Carlton). 2020; 25: 535-543
        • Gibson CM
        • Dumaine RL
        • Gelfand EV
        • Murphy SA
        • Morrow DA
        • Wiviott SD
        • Giugliano RP
        • Cannon CP
        • Antman EM
        • Braunwald E
        • TIMI Study Group
        Association of glomerular filtration rate on presentation with subsequent mortality in non-ST-segment elevation acute coronary syndrome; observations in 13,307 patients in five TIMI trials.
        Eur Heart J. 2004; 25: 1998-2005
        • Bhatia S
        • Arora S
        • Bhatia SM
        • Al-Hijji M
        • Reddy YNV
        • Patel P
        • Rihal CS
        • Gersh BJ
        • Deshmukh A.
        Non-ST-segment-elevation myocardial infarction Among patients With chronic kidney disease: A propensity score-matched comparison of percutaneous coronary intervention Versus conservative management.
        J Am Heart Assoc. 2018; 7
        • Anavekar NS
        • McMurray JJ
        • Velazquez EJ
        • Solomon SD
        • Kober L
        • Rouleau JL
        • White HD
        • Nordlander R
        • Maggioni A
        • Dickstein K
        • Zelenkofske S
        • Leimberger JD
        • Califf RM
        • Pfeffer MA.
        Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction.
        N Engl J Med. 2004; 351: 1285-1295
        • Mehran R
        • Nikolsky E
        • Lansky AJ
        • Kirtane AJ
        • Kim YH
        • Feit F
        • Manoukian S
        • Moses JW
        • Ebrahimi R
        • Ohman EM
        • White HD
        • Pocock SJ
        • Dangas GD
        • Stone GW.
        Impact of chronic kidney disease on early (30-day) and late (1-year) outcomes of patients with acute coronary syndromes treated with alternative antithrombotic treatment strategies: an ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) substudy.
        JACC Cardiovasc Interv. 2009; 2: 748-757
        • Medi C
        • Chew DP
        • Amerena J
        • Coverdale S
        • Soman A
        • Astley C
        • Rankin J
        • Brieger D.
        An invasive management strategy is associated with improved outcomes in high-risk acute coronary syndromes in patients with chronic kidney disease.
        Intern Med J. 2011; 41: 743-750
        • Patti G
        • Ricottini E
        • Nenna A
        • Cavallari I
        • Antonucci E
        • Calabrò P
        • Cirillo P
        • Gresele P
        • Palareti G
        • Pengo V
        • Pignatelli P
        • Bisignani A
        • Marcucci R.
        Impact of chronic renal failure on ischemic and Bleeding Events at 1 year in Patients with Acute Coronary Syndrome (from the Multicenter START antiplatelet Registry).
        Am J Cardiol. 2018; 122: 936-943
        • James S
        • Budaj A
        • Aylward P
        • Buck KK
        • Cannon CP
        • Cornel JH
        • Harrington RA
        • Horrow J
        • Katus H
        • Keltai M
        • Lewis BS
        • Parikh K
        • Storey RF
        • Szummer K
        • Wojdyla D
        • Wallentin L.
        Ticagrelor versus clopidogrel in acute coronary syndromes in relation to renal function: results from the Platelet Inhibition and Patient Outcomes (Plato) trial.
        Circulation. 2010; 122: 1056-1067
        • Wöhrle J
        • Seeger J
        • Lahu S
        • Mayer K
        • Bernlochner I
        • Gewalt S
        • Menichelli M
        • Witzenbichler B
        • Hochholzer W
        • Sibbing D
        • Cassese S
        • Angiolillo DJ
        • Hemetsberger R
        • Valina C
        • Kufner S
        • Xhepa E
        • Hapfelmeier A
        • Sager HB
        • Joner M
        • Richardt G
        • Laugwitz KL
        • Neumann FJ
        • Schunkert H
        • Schüpke S
        • Kastrati A
        • Ndrepepa G.
        Ticagrelor or prasugrel in patients with acute coronary syndrome in relation to estimated glomerular filtration rate.
        JACC Cardiovasc Interv. 2021; 14: 1857-1866
        • Ndrepepa G
        • Mehilli J
        • Schulz S
        • Iijima R
        • Keta D
        • Byrne RA
        • Pache J
        • Seyfarth M
        • Schömig A
        • Kastrati A.
        Patterns of presentation and outcomes of patients with acute coronary syndromes.
        Cardiology. 2009; 113: 198-206
        • Parsh J
        • Seth M
        • Aronow H
        • Dixon S
        • Heung M
        • Mehran R
        • Gurm HS.
        Choice of estimated glomerular filtration rate equation impacts drug-dosing recommendations and risk stratification in patients With chronic kidney disease undergoing percutaneous coronary interventions.
        J Am Coll Cardiol. 2015; 65: 2714-2723
        • Ndrepepa G
        • Holdenrieder S
        • Neumann FJ
        • Lahu S
        • Cassese S
        • Joner M
        • Xhepa E
        • Kufner S
        • Wiebe J
        • Laugwitz KL
        • Gewalt S
        • Schunkert H
        • Kastrati A.
        Prognostic value of glomerular function estimated by Cockcroft-Gault creatinine clearance, MDRD-4, CKD-EPI and European Kidney Function Consortium equations in patients with acute coronary syndromes.
        Clin Chim Acta. 2021; 523: 106-113
        • Blicher TM
        • Hommel K
        • Olesen JB
        • Torp-Pedersen C
        • Madsen M
        • Kamper AL.
        Less use of standard guideline-based treatment of myocardial infarction in patients with chronic kidney disease: a Danish nation-wide cohort study.
        Eur Heart J. 2013; 34: 2916-2923
        • Patel B
        • Shah M
        • Dusaj R
        • Maynard S
        • Patel N.
        Percutaneous coronary intervention and inpatient mortality in patients with advanced chronic kidney disease presenting with acute coronary syndrome.
        Proc (Bayl Univ Med Cent). 2017; 30: 400-403
        • Tello-Montoliu A
        • Ruiz-Nodar JM
        • Esteve-Pastor MA
        • Véliz-Martínez A
        • Orenes-Piñero E
        • Macías-Villanego MJ
        • Lozano T
        • Carrillo-Alemán L
        • Vicente-Ibarra N
        • Pernias-Escrig V
        • Martínez-Martínez JG
        • Rivera-Caravaca JM
        • Marín F.
        Chronic kidney disease and third-generation P2Y12 inhibitors use in patients with acute coronary syndrome: impact on the prognosis at 1 year.
        J Clin Pharmacol. 2019; 59: 295-302
        • Cannon CP
        • Weintraub WS
        • Demopoulos LA
        • Vicari R
        • Frey MJ
        • Lakkis N
        • Neumann FJ
        • Robertson DH
        • DeLucca PT
        • DiBattiste PM
        • Gibson CM
        • Braunwald E
        • TACTICS
        Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban.
        N Engl J Med. 2001; 344: 1879-1887
        • Lagerqvist B
        • Husted S
        • Kontny F
        • Ståhle E
        • Swahn E
        • Wallentin L
        Fast Revascularisation during InStability in Coronary artery disease (FRISC-II) Investigators. 5-year outcomes in the FRISC-II randomised trial of an invasive versus a non-invasive strategy in non-ST-elevation acute coronary syndrome: a follow-up study.
        Lancet. 2006; 368: 998-1004
        • Schüpke S
        • Neumann FJ
        • Menichelli M
        • Mayer K
        • Bernlochner I
        • Wöhrle J
        • Richardt G
        • Liebetrau C
        • Witzenbichler B
        • Antoniucci D
        • Akin I
        • Bott-Flügel L
        • Fischer M
        • Landmesser U
        • Katus HA
        • Sibbing D
        • Seyfarth M
        • Janisch M
        • Boncompagni D
        • Hilz R
        • Rottbauer W
        • Okrojek R
        • Möllmann H
        • Hochholzer W
        • Migliorini A
        • Cassese S
        • Mollo P
        • Xhepa E
        • Kufner S
        • Strehle A
        • Leggewie S
        • Allali A
        • Ndrepepa G
        • Schühlen H
        • Angiolillo DJ
        • Hamm CW
        • Hapfelmeier A
        • Tölg R
        • Trenk D
        • Schunkert H
        • Laugwitz KL
        • Kastrati A
        • ISAR-REACT
        Ticagrelor or prasugrel in patients with acute coronary syndromes.
        N Engl J Med. 2019; 381: 1524-1534
        • Menichelli M
        • Neumann FJ
        • Ndrepepa G
        • Mayer K
        • Wöhrle J
        • Bernlochner I
        • Richardt G
        • Witzenbichler B
        • Sibbing D
        • Gewalt S
        • Angiolillo DJ
        • Lahu S
        • Hamm CW
        • Hapfelmeier A
        • Trenk D
        • Laugwitz KL
        • Schunkert H
        • Schüpke S
        • Kastrati A.
        Age- and weight-adapted dose of prasugrel versus standard dose of ticagrelor in patients with acute coronary syndromes: results From a randomized trial.
        Ann Intern Med. 2020; 173: 436-444
        • Levey AS
        • Stevens LA
        • Schmid CH
        • Zhang YL
        • Castro 3rd, AF
        • Feldman HI
        • Kusek JW
        • Eggers P
        • Van Lente F
        • Greene T
        • Coresh J
        CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration). A new equation to estimate glomerular filtration rate.
        Ann Intern Med. 2009; 150: 604-612
        • Thygesen K
        • Alpert JS
        • Jaffe AS
        • Simoons ML
        • Chaitman BR
        • Thygesen K
        • Alpert JS
        • White HD
        • Biomarker S
        • Jaffe AS
        • Katus HA
        • Apple FS
        • Lindahl B
        • Morrow DA
        • Subcommittee ECG
        • Chaitman BR
        • Clemmensen PM
        • Johanson P
        • Hod H
        • Imaging S
        • Underwood R
        • Bax JJ
        • Bonow JJ
        • Pinto F
        • Gibbons RJ
        • Classification S
        • Fox KA
        • Atar D
        • Newby LK
        • Galvani M
        • Hamm CW
        • Intervention S
        • Uretsky BF
        • Steg PG
        • Wijns W
        • Bassand JP
        • Menasche P
        • Ravkilde J
        • Ohman EM
        • Antman EM
        • Wallentin LC
        • Armstrong PW
        • Simoons ML
        • Januzzi JL
        • Nieminen MS
        • Gheorghiade M
        • Filippatos G
        • Trials Registries S
        • Luepker RV
        • Fortmann SP
        • Rosamond WD
        • Levy D
        • Wood D
        • Trials Registries S
        • Smith SC
        • Hu D
        • Lopez-Sendon JL
        • Robertson RM
        • Weaver D
        • Tendera M
        • Bove AA
        • Parkhomenko AN
        • Vasilieva EJ
        • Mendis S
        • Guidelines ESCCfP
        • Bax JJ
        • Baumgartner H
        • Ceconi C
        • Dean V
        • Deaton C
        • Fagard R
        • Funck-Brentano C
        • Hasdai D
        • Hoes A
        • Kirchhof P
        • Knuuti J
        • Kolh P
        • McDonagh T
        • Moulin C
        • Popescu BA
        • Reiner Z
        • Sechtem U
        • Sirnes PA
        • Tendera M
        • Torbicki A
        • Vahanian A
        • Windecker S
        • Document R
        • Morais J
        • Aguiar C
        • Almahmeed W
        • Arnar DO
        • Barili F
        • Bloch KD
        • Bolger AF
        • Botker HE
        • Bozkurt B
        • Bugiardini R
        • Cannon C
        • de Lemos J
        • Eberli FR
        • Escobar E
        • Hlatky M
        • James S
        • Kern KB
        • Moliterno DJ
        • Mueller C
        • Neskovic AN
        • Pieske BM
        • Schulman SP
        • Storey RF
        • Taubert KA
        • Vranckx P
        • Wagner DR
        • White HD, Joint ESC/ACCF/AHA/WHF Task Force for Universal Definition of Myocardial Infarction
        • Trials, Registries S
        • Trials, Registries S
        Third universal definition of myocardial infarction.
        J Am Coll Cardiol. 2012; 60: 1581-1598
        • Mehran R
        • Rao SV
        • Bhatt DL
        • Gibson CM
        • Caixeta A
        • Eikelboom J
        • Kaul S
        • Wiviott SD
        • Menon V
        • Nikolsky E
        • Serebruany V
        • Valgimigli M
        • Vranckx P
        • Taggart D
        • Sabik JF
        • Cutlip DE
        • Krucoff MW
        • Ohman EM
        • Steg PG
        • White H.
        Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium.
        Circulation. 2011; 123: 2736-2747
        • Lu R
        • Tang F
        • Zhang Y
        • Zhu X
        • Zhu S
        • Wang G
        • Jiang Y
        • Fan Z.
        Comparison of drug-eluting and bare metal stents in patients with chronic kidney disease: an updated systematic review and meta-analysis.
        J Am Heart Assoc. 2016; 5
        • Wiviott SD
        • Braunwald E
        • McCabe CH
        • Montalescot G
        • Ruzyllo W
        • Gottlieb S
        • Neumann FJ
        • Ardissino D
        • De Servi S
        • Murphy SA
        • Riesmeyer J
        • Weerakkody G
        • Gibson CM
        • Antman EM
        TRITON-TIMI 38 Investigators. Prasugrel versus clopidogrel in patients with acute coronary syndromes.
        N Engl J Med. 2007; 357: 2001-2015
        • Gurbel PA
        • Erlinge D
        • Ohman EM
        • Neely B
        • Neely M
        • Goodman SG
        • Huber K
        • Chan MY
        • Cornel JH
        • Brown E
        • Zhou C
        • Jakubowski JA
        • White HD
        • Fox KA
        • Prabhakaran D
        • Armstrong PW
        • Tantry US
        • Roe MT
        • Trilogy ACS
        Platelet Function Substudy Investigators. Platelet function during extended prasugrel and clopidogrel therapy for patients with ACS treated without revascularization: the TRILOGY ACS platelet function substudy.
        JAMA. 2012; 308: 1785-1794
        • Melloni C
        • Cornel JH
        • Hafley G
        • Neely ML
        • Clemmensen P
        • Zamoryakhin D
        • Prabhakaran D
        • White HD
        • Fox KA
        • Ohman EM
        • Armstrong PW
        • Roe MT.
        Impact of chronic kidney disease on long-term ischemic and bleeding outcomes in medically managed patients with acute coronary syndromes: insights from the TRILOGY ACS Trial.
        Eur Heart J Acute Cardiovasc Care. 2016; 5: 443-454
        • Baber U
        • Chandrasekhar J
        • Sartori S
        • Aquino M
        • Kini AS
        • Kapadia S
        • Weintraub W
        • Muhlestein JB
        • Vogel B
        • Faggioni M
        • Farhan S
        • Weiss S
        • Strauss C
        • Toma C
        • DeFranco A
        • Baker BA
        • Keller S
        • Effron MB
        • Henry TD
        • Rao S
        • Pocock S
        • Dangas G
        • Mehran R.
        Associations Between chronic kidney disease and outcomes with use of prasugrel versus clopidogrel in patients with acute coronary syndrome undergoing percutaneous coronary intervention: A report From the Prometheus study.
        JACC Cardiovasc Interv. 2017; 10: 2017-2025